ERC funds development of new treatments for lung disease

by Centre for Genomic Regulation

3 years ago
lung disease, ERC, Mycoplasma pneumoniae, bacterium, lung

Today researchers at the CRG are amongst some of the world’s leading scientists in receiving funding from the European Research Council’s Advanced Grants Competition. The grant is dedicated lon...

Identified a potential target to treat lung cancer

by IRB Barcelona - Instituto de Investigación Biomédica

3 years ago
lung, Cancer, personalised medicine

As an approach to personalised medicine, the work proposes the HMCES sensor of DNA damage as a target to treat some of the most aggressive types of lung tumours. The results have been published in PL...

Flomics Investment opportunity

by Flomics Biotech SL

3 years ago
investment, genomics, Flomics, liquid biopsy, colon cancer, lung

Flomics Biotech, a startup from the Barcelona Biomedical Research Park (PRBB) operating in the genomics and liquid biopsy fields is excited to announce the launch of its seed investment round of 500.0...

CNIO researchers develop an effective strategy to induce regression in lung tumours caused by the KRAS oncogene in mice

by CNIO - Centro Nacional de Investigaciones Oncológicas

4 years ago
lung, cancer, KRAS, pancreas

Researchers from the Experimental Oncology Group at the CNIO have achieved complete remission of 25% of lung tumours caused by the KRAS oncogene in mice by inactivating CDK4 and RAF1, two genes that a...

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal

by Ability Pharma

4 years ago
Autophagy, cancer, cytotoxic autophagy, lung, endometrial

The biopharmaceutical company Ability Pharmaceuticals SL announced today that the full description of the mechanism of action of ABTL0812 has been published in the prestigious Autophagy journal (impac...

DRUG TARGETS: The heat shock protein 90 inhibitor ganetespib failed to improve outcomes when added to chemotherapy in advance NSCLC (phase III GALAXY-2 trial). Samples were obtained for biomarker studies; results not yet reported

by OncoDNA

4 years ago
protein, cancer, lung

Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non–Small-Cell Lung Cancer (GALAXY-2)

LUNG CANCER: Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 tria

by OncoDNA

4 years ago
LUNG CANCER, EGFR, ZENITH20 tria, ZENITH20 trial’s Cohort 1, lung

Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 trial. For patients with pre-treated NSCLC with EGFR exon 20 insertion mut...

New advances in the treatment of advanced lung cancer

by Fundació Bosch i Gimpera

4 years ago
smoking, Boehringer Ingelheim, Nintedanib, cancer, lung

The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the ...

ORYZON’s iadademstat shows efficacy signs in relapsed SCLC

by Oryzon Genomics

5 years ago
iadademstat, cancer, lung, CLEPSIDRA

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, today p...

Two new grants awarded to advance potential treatments of lung cancer

by Centre for Genomic Regulation

5 years ago
help, cancer, lung

The lab of Juan Valcárcel has been awarded a grant from the UK-based Research Charity Worldwide Cancer Research as well as a PRODUCTE grant, 2018 Knowledge Industry, from the Catalonian Government.

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients

by Ability Pharma

8 years ago
ABTL0812, carboplatin, paclitaxel, cancer, lung, endometrial cancer

ABTL0812 is administered in combination with carboplatin and paclitaxel. Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead...

Discovery of why colon cancer metastasis always follows the same invasive pattern

by Professional Newco

10 years ago
cancer, colon, liver, lung

Roger Gomis’ team, in collaboration with another two groups in IRB Barcelona’s Oncology Programme, reveal in Nature Cell Biology the genes and mechanisms that allow liver metastasis to colonize th...